Page 4 - Renal Dysfunction News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Applications based on positive results from the Phase 3 CheckMate -648 trial, in which both Opdivo -based combinations demonstrated a significant survival benefit over chemotherapy alone Bristol Myers Squibb today announced that the European Medicines Agency has validated its Type II Variation Marketing Authorization Applications for both Opdivo in combination with Yervoy and Opdivo in combination with ...

Is there one best DOAC renal dosing adjustment method?

Long-term data from PACIFIC Phase III trial at ASCO showed 33% of patients remained progression-free at five years Longest-ever survival reported in a Phase III immunotherapy trial in this setting ...

Patients treated with Opdivo plus Yervoy with two cycles of chemotherapy showed sustained improvements in overall survival and progression-free survival and increased duration of response vs. chemotherapy at two years Dual immunotherapy-based combination demonstrated clinical benefit across key subgroups of patients, regardless of PD-L1 expression level or histology Data to be featured in an oral presentation during … Patients treated with Opdivo plus Yervoy with two cycles of chemotherapy showed sustained improvements in overall survival and progression-free survival and increased d...

49% of patients treated with Opdivo plus Yervoy were alive at 6.5 years and 77% of these patients remained treatment-free Data to be featured in an oral presentation during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3 clinical trial, demonstrating durable improvement in survival with first-line Opdivo (nivolumab) plus Opdivo monotherapy, versus Yervoy alone, in patients with advanced melanoma. With a minimum follow-...